多発性骨髄腫の市場規模、シェア、成長分析、薬剤クラス別、治療法別、流通チャネル別、地域別 - 産業予測、2024年～2031年

世界の多発性骨髄腫の市場規模は、2022年に219億8,000万米ドルとなり、2023年の253億米ドルから、2031年までには779億3,000万米ドルに成長し、予測期間（2024年～2031年）のCAGRは15.1％で成長する見通しです。

多発性骨髄腫市場は、主に形質細胞を侵すこの稀な血液がんに対する認識の高まりと罹患率の上昇に牽引され、大きな勢いを見せています。新たな治療薬が続々と登場する中、競合情勢は進化しており、市場参入企業の間で治療に関する専門知識が著しく向上しています。Globocan 2020 dataなどの報告書によると、世界で新たにがんと診断された患者数は1,929万2,789人で、がんに関連した死亡者数は約1,000万人です。国際がん研究機関（IARC）は、この数字は2031年までに2,750万人の新規発症者と、1,630万人の死亡者までにエスカレートし、男性は女性の1.5倍のリスクに直面すると予測しています。主要な危険因子としては、喫煙、飲酒などのライフスタイルの選択、男性の肥満率の高さなどが挙げられます。市場の成長に寄与しているのは、血液がんの罹患率の増加と、ヘルスケア・インフラ、研究、治療オプションに対する需要の高まりです。しかし、世界の多発性骨髄腫市場の拡大は、発展途上国における治療率の低さによってやや抑制されています。現状では、米国の多発性骨髄腫市場は、ヘルスケア部門がこの課題との闘いに重点を置いていることから、今後数年間は持続可能な年間平均成長率（CAGR）を維持すると予測されています。

目次

イントロダクション

• 調査の目的
• 定義
• 市場範囲

調査手法

• 情報調達
• 二次・一次情報源
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 市場概要見通し
• 供給需要動向分析
• セグメント別機会分析

市場力学と見通し

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• ポーターの分析

主要な市場の考察

• 主要な成功要因
• 競合の程度
• 主要な投資機会
• 市場のエコシステム
• バリューチェーン分析
• 原材料の分析
• 価格分析
• 消費者行動分析
• PESTEL分析

多発性骨髄腫市場：薬剤クラス別

• 市場概要
• プロテアソーム阻害剤
• 免疫調節薬
• モノクローナル抗体
• ステロイド

多発性骨髄腫市場：治療法別

• 市場概要
• 免疫療法
• 化学療法
• 放射線治療
• 幹細胞移植

多発性骨髄腫市場：流通チャネル別

• 市場概要
• 病院
• 小売り
• オンライン薬局

多発性骨髄腫市場規模：地域別

• 市場概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ（MEA）
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ地域

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主要な市場企業が採用した戦略
• 市場における最近の活動
• 主要企業の市場シェア（2023年）

主要企業プロファイル

• Bristol-Myers Squibb Company（US）
• Amgen Inc.（US）
• Johnson & Johnson（Janssen Pharmaceuticals）（US）
• Novartis AG（Switzerland）
• Sanofi（France）
• Takeda Pharmaceutical Company Limited（Japan）
• Pfizer Inc.（US）
• Celgene Corporation（Bristol-Myers Squibb Company）（US）
• AbbVie Inc.（US）
• Genentech, Inc.（F. Hoffmann-La Roche Ltd）（US）
• Karyopharm Therapeutics（US）
• Teva Pharmaceutical Industries Ltd.（Israel）
• ONO Pharmaceutical Co., Ltd.（Japan）
• Merck & Co., Inc.（US）
• Eli Lilly and Company（US）
• GlaxoSmithKline plc（UK）
• Bayer AG（Germany）
• Takeda Oncology（Millennium Pharmaceuticals）（Japan）
• Oncopeptides AB（Sweden）
• Bluebird Bio, Inc.（US）

Global Multiple Myeloma Market size was valued at USD 21.98 billion in 2022 and is poised to grow from USD 25.30 billion in 2023 to USD 77.93 billion by 2031, growing at a CAGR of 15.1% in the forecast period (2024-2031).

The multiple myeloma market is experiencing significant momentum driven by increasing awareness and rising incidence of this rare blood cancer, primarily affecting plasma cells. As new therapeutics continue to emerge, the competitive landscape is evolving, with a marked uptick in treatment expertise among leading market participants. Reports, such as the Globocan 2020 data, highlight a staggering 19,292,789 new cancer diagnoses worldwide, alongside nearly 10 million cancer-related fatalities. The International Agency for Research on Cancer (IARC) projects that these numbers will escalate to 27.5 million new cases and 16.3 million deaths by 2031, with men facing a 1.5-fold higher risk than women. Key risk factors include lifestyle choices like smoking, alcohol use, and higher obesity rates among men, while the disease predominantly affects older adults, particularly those aged 55 to 65. Contributing to market growth is the increasing incidence of hematological cancers and a growing demand for healthcare infrastructure, research, and treatment options. However, the proliferation of the global multiple myeloma market is somewhat curtailed by low treatment rates in developing nations. As it stands, the US multiple myeloma market is anticipated to maintain a sustainable compound annual growth rate (CAGR) in the forthcoming years, as the healthcare sector intensifies its focus on combating this challenging disease.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multiple Myeloma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Multiple Myeloma Market Segmental Analysis

Global Multiple Myeloma Market is segmented on the drug class, therapy, distribution channel, and region. By drug class, market is segmented into Proteasome Inhibitors, Immunomodulatory Drugs, Monoclonal Antibodies, and Steroids. By therapy, market is segmented into immunotherapy, chemotherapy, radiation therapy, and stem cell transplant. By distribution channel, market is segmented into hospital, retail, and online pharmacies. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver of the Global Multiple Myeloma Market

The global multiple myeloma market is significantly driven by the increasing adoption of monoclonal antibodies, which are heralded for their high safety profile and targeted action against myeloma cells. Advances in nanomedicine and microRNA therapies, alongside the ongoing development of effective and safe treatments, are further propelling market growth. The integration of monoclonal antibodies, like Darzalex and Empliciti, with existing therapies enhances treatment efficacy, attracting clinician preference. Additionally, the rising incidence of hematological cancers, particularly multiple myeloma linked to specific genetic mutations, coupled with an aging population and rising healthcare costs, are amplifying the demand for innovative treatment solutions within this market.

Restraints in the Global Multiple Myeloma Market

The global multiple myeloma market is significantly restrained by low treatment rates in emerging nations, primarily driven by the high cost of treatments, which limits patient access. Furthermore, the scarcity of skilled healthcare professionals and inadequate healthcare infrastructure in these regions compound the issue, hindering effective diagnosis and treatment. The COVID-19 pandemic has exacerbated this situation, resulting in a notable decline in clinical visits and heightened reluctance among patients to seek medical care. Additionally, a pervasive lack of public awareness regarding multiple myeloma remains a critical barrier, ultimately impeding the market's growth potential throughout the forecast period.

Market Trends of the Global Multiple Myeloma Market

The global multiple myeloma market is experiencing a significant upward trend driven by increased research and development activities. This surge is fostering the introduction of novel therapies, evidenced by a rise in drug approvals and market entries, particularly in monoclonal antibodies like Darzalex and Empliciti. These advancements not only offer innovative treatment options, extending relapse intervals for patients, but also complement traditional therapies such as Revlimid and Velcade. Additionally, the emergence of second-generation proteasome inhibitors like Ninlaro and Kyprolis further diversifies treatment strategies, enhancing patient outcomes and solidifying the market's growth trajectory in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree Of Competition
• Top Investment Pockets
• Ecosystem Of the Market
• Value Chain Analysis
• Raw Material Analysis
• Pricing Analysis
• Consumer Behaviour Analysis
• PESTEL Analysis

Multiple Myeloma Market, By Drug Class

• Market Overview
• Proteasome Inhibitors
• Immunomodulatory Drugs
• Monoclonal Antibodies
• Steroids

Multiple Myeloma Market, By Therapy

• Market Overview
• Immunotherapy
• Chemotherapy
• Radiation Therapy
• Stem Cell Transplant

Multiple Myeloma Market, By Distribution Channel

• Market Overview
• Hospital
• Retail
• Online Pharmacies

Multiple Myeloma Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (Janssen Pharmaceuticals) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (Bristol-Myers Squibb Company) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc. (F. Hoffmann-La Roche Ltd) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karyopharm Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ONO Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Oncology (Millennium Pharmaceuticals) (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oncopeptides AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bluebird Bio, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments